BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended March 31, 2001
Business Overview: BD operates in three reportable segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. The company manufactures and distributes medical devices, diagnostic products, and life science tools.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 4% for the quarter and 1% year-to-date. Growth was unfavorably impacted by foreign currency translation (Euro and Yen), which reduced revenues by an estimated $31 million for the quarter and $77 million year-to-date. Excluding currency effects, international revenues grew 9% (quarter) and 7% (YTD).
• Segment Performance:
  • Medical Systems: Revenues up 4% (7% excluding currency). Operating income improved significantly when excluding $13 million in voluntary product recall costs from the prior year.
  • Clinical Lab: Revenues up 2%. Operating income was adversely affected by decreased sales of high-margin flu products compared to the prior year.
  • Biosciences: Revenues up 10% (14% excluding currency), driven by all product groups and recent acquisitions.
• Profitability: Operating margin improved to 18.4% for the quarter (vs. 16.2% prior year), driven by lower operating expenses and the absence of prior-year recall costs. Net income remained relatively flat quarter-over-quarter but declined year-to-date due to a $33 million gain on the sale of an investment in the prior year.
• Acquisitions: Completed the acquisition of Gentest Corporation on January 10, 2001, for approximately $29 million in cash.

Guidance, Outlook, and Risks

• Outlook: Management expects the full-year tax rate to be approximately 24%. Capital spending for fiscal 2001 is expected to be about $376 million, similar to the prior year.
• Restructuring: The company is executing a fiscal 2000 restructuring plan targeting $30 million in annual savings, primarily from salary reductions. A 1998 restructuring plan regarding the Hancock facility closure is now expected to be completed by December 2002.
• Legal Proceedings:
  • Latex Cases: 457 claims received to date regarding latex glove reactions.
  • Critikon Litigation: Settled for $5 million ($3 million initial + $2 million final payment).
  • Braun Litigation: Suspended without prejudice until after May 15, 2001.
  • RTI Litigation: New lawsuit filed regarding antitrust laws.
• Risks: Key risks include foreign currency fluctuations, competitive pricing pressures, healthcare cost containment, raw material costs, and regulatory approvals for new products.

Investor Verification Checklist

• Currency Impact: Verify the extent to which foreign exchange rates (specifically Euro and Yen) continue to suppress reported revenue growth.
• Product Mix: Assess the sustainability of revenue growth in the Biosciences segment versus the decline in high-margin flu product sales in the Clinical Lab segment.
• Restructuring Costs: Monitor the timeline and cost overruns associated with the delayed closure of the Hancock surgical blade facility.
• Legal Reserves: Review the adequacy of reserves for ongoing latex litigation and potential antitrust claims.
• Acquisition Integration: Evaluate the financial contribution of the Gentest Corporation acquisition in upcoming quarters.